Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:accessories |
during initial rollout
|
| gptkbp:appointed_by |
injection
|
| gptkbp:approves |
gptkb:U._S._Food_and_Drug_Administration
|
| gptkbp:availability |
limited initially
|
| gptkbp:campaigns |
public awareness campaigns
|
| gptkbp:clinical_trial |
conducted prior to approval
|
| gptkbp:communication |
critical for uptake
|
| gptkbp:developed_by |
gptkb:Centers_for_Disease_Control_and_Prevention
|
| gptkbp:distribution |
nationwide in the U. S.
|
| gptkbp:events |
conducted post-vaccination
|
| gptkbp:healthcare |
pandemic influenza preparedness
influenced by scientific evidence |
| https://www.w3.org/2000/01/rdf-schema#label |
2009 H1 N1 vaccine
|
| gptkbp:is_effective_against |
approximately 60% to 70%
conducted post-deployment |
| gptkbp:is_vulnerable_to |
requires refrigeration
reduced hospitalizations post-marketing surveillance reduced mortality rates September 2009 varies by population updated annually provided to the public monitored continuously recommended annually coordinated with international health organizations adapted based on emerging data addressed through federal support coordinated with local health departments important for future outbreaks important for future preparedness increased during outbreak increased during the pandemic key to increasing uptake mixed due to misinformation monovalent vaccine ongoing for future strains showed significant public health benefits studied in various demographics |
| gptkbp:manufacturer |
multiple pharmaceutical companies
|
| gptkbp:offers |
gptkb:2009
|
| gptkbp:produced_by |
accelerated due to pandemic
|
| gptkbp:public_awareness |
integrated into broader health initiatives
|
| gptkbp:side_effect |
fatigue
headache mild fever soreness at injection site rare serious allergic reactions studied in follow-up research |
| gptkbp:suitable_for |
gptkb:World_Health_Organization
high-risk populations |
| gptkbp:target_audience |
children and young adults
|
| gptkbp:targets |
gptkb:H1_N1_influenza
|
| gptkbp:type |
inactivated vaccine
|
| gptkbp:volunteer_opportunities |
targeted vulnerable communities
|
| gptkbp:bfsParent |
gptkb:2009_H1_N1_pandemic
|
| gptkbp:bfsLayer |
6
|